Congratulations, Sangeet!

We are excited that Sangeet's pilot project proposal, " Chemokine Regulation of the Leptomeningeal Metastasis of Medulloblastoma " has been funded by the Knight Cancer Institute Translational Research Group and made possible by the Schnitzer Investment Corp.  
  
way to go, Sangeet!
  
  

To  Friends at the Schnitzer Investment Corp, our team and I are grateful that you have made possible our pilot grant.  Preventing the spread of brain tumor cells to the spine is an important issue for children of Oregon and across the world.  We hope to take the opportunity you have created for us to study this cancer-related process to not only understand how it occurs, but also to understand how to prevent it (or to treat it if already established).  As you have proven, the community is always an important part of new and innovative research endeavors.  Charles

  

  

Lyla Nsouli Foundation funds Supplement to the DIPG Consortium

We are grateful to the The Lyla Nsouli Foundation for Children’s Brain Cancer Research for the $28,000 supplement to our TheCureStartsNow funded project entitled, "Rapid Preclinical Development of a Targeted Therapy Combination for DIPG".  This supplement allows us to expand our six institution consortium in North America to include 2 other expert laboratories in Europe:
  

• Dannis G. van Vuurden MD, MSc, & Esther Hulleman, VU Cancer Center Amsterdam, and
• Jacques Grill, Institut Gustave-Roussy, Villejuif, France

The ultimate goal is to move the most effective single agent or combination therapy forward to early phase clinical trials in the next 18-24 months. This is the first time that a group of basic and translational scientists and physicians from eight institutions throughout North America and Europe have come together as a consortium to focus on DIPGs and to focus on a bench-to-bedside approach to rationally target therapy for children with DIPGs.

  
For the Open Science Forum week to week update of this project, click here.